160 related articles for article (PubMed ID: 37378935)
1. Genomic Index of Sensitivity to Chemotherapy for Triple Negative Breast Cancer.
Sameer C A; Shah M; Nandy D; Gupta R
Asian Pac J Cancer Prev; 2023 Jun; 24(6):2043-2053. PubMed ID: 37378935
[TBL] [Abstract][Full Text] [Related]
2. Identification of chemoresistance-associated miRNAs in breast cancer.
Lou W; Liu J; Ding B; Xu L; Fan W
Cancer Manag Res; 2018; 10():4747-4757. PubMed ID: 30425571
[TBL] [Abstract][Full Text] [Related]
3. Identification of invasion-metastasis-associated microRNAs in hepatocellular carcinoma based on bioinformatic analysis and experimental validation.
Lou W; Chen J; Ding B; Chen D; Zheng H; Jiang D; Xu L; Bao C; Cao G; Fan W
J Transl Med; 2018 Sep; 16(1):266. PubMed ID: 30268144
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatic identification of chemoresistance-associated microRNAs in breast cancer based on microarray data.
Wang YW; Zhang W; Ma R
Oncol Rep; 2018 Mar; 39(3):1003-1010. PubMed ID: 29328395
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer.
Ouyang M; Li Y; Ye S; Ma J; Lu L; Lv W; Chang G; Li X; Li Q; Wang S; Wang W
PLoS One; 2014; 9(5):e96228. PubMed ID: 24788655
[TBL] [Abstract][Full Text] [Related]
6. Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis.
Qattan A; Al-Tweigeri T; Alkhayal W; Suleman K; Tulbah A; Amer S
Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33918859
[TBL] [Abstract][Full Text] [Related]
7. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of two miRNAs promotes proliferation, hepatitis B virus amplification, migration and invasion of hepatocellular carcinoma cells: evidence from bioinformatic analysis and experimental validation.
Liu Y; Cao Y; Cai W; Wu L; Zhao P; Liu XG
PeerJ; 2020; 8():e9100. PubMed ID: 32377460
[TBL] [Abstract][Full Text] [Related]
9. Identification of the differential expression of genes and upstream microRNAs in small cell lung cancer compared with normal lung based on bioinformatics analysis.
Li X; Ma C; Luo H; Zhang J; Wang J; Guo H
Medicine (Baltimore); 2020 Mar; 99(11):e19086. PubMed ID: 32176034
[TBL] [Abstract][Full Text] [Related]
10. A panel of miRNAs as prognostic markers for African-American patients with triple negative breast cancer.
Turkistani S; Sugita BM; Fadda P; Marchi R; Afsari A; Naab T; Apprey V; Copeland RL; Campbell MC; Cavalli LR; Kanaan Y
BMC Cancer; 2021 Jul; 21(1):861. PubMed ID: 34315420
[TBL] [Abstract][Full Text] [Related]
11. Downregulations of miR-449a and miR-145-5p Act as Prognostic Biomarkers for Endometrial Cancer.
Wu X; Han Y; Liu F; Ruan L
J Comput Biol; 2020 May; 27(5):834-844. PubMed ID: 31513434
[TBL] [Abstract][Full Text] [Related]
12. Identification of potential miRNA-mRNA regulatory network contributing to pathogenesis of HBV-related HCC.
Lou W; Liu J; Ding B; Chen D; Xu L; Ding J; Jiang D; Zhou L; Zheng S; Fan W
J Transl Med; 2019 Jan; 17(1):7. PubMed ID: 30602391
[TBL] [Abstract][Full Text] [Related]
13. A panel of eight microRNAs is a good predictive parameter for triple-negative breast cancer relapse.
Hong HC; Chuang CH; Huang WC; Weng SL; Chen CH; Chang KH; Liao KW; Huang HD
Theranostics; 2020; 10(19):8771-8789. PubMed ID: 32754277
[No Abstract] [Full Text] [Related]
14. Identification of key microRNAs and hub genes in non-small-cell lung cancer using integrative bioinformatics and functional analyses.
Song F; Xuan Z; Yang X; Ye X; Pan Z; Fang Q
J Cell Biochem; 2020 Mar; 121(3):2690-2703. PubMed ID: 31692035
[TBL] [Abstract][Full Text] [Related]
15. A systems biology approach and in vitro experiment indicated Rapamycin targets key cancer and cell cycle-related genes and miRNAs in triple-negative breast cancer cells.
Tafti A; Shojaei S; Zali H; Karima S; Mohammadi-Yeganeh S; Mondanizadeh M
Mol Carcinog; 2023 Dec; 62(12):1960-1973. PubMed ID: 37787375
[TBL] [Abstract][Full Text] [Related]
16. Identification of Hub Genes and Upstream Regulatory Factors Based on Cell Adhesion in Triple-negative Breast Cancer by Integrated Bioinformatical Analysis.
Han YH; Wang Y; Lee SJ; Mao YY; Jiang P; Sun HN; Jin MH; Kwon T
Anticancer Res; 2023 Jul; 43(7):2951-2964. PubMed ID: 37351977
[TBL] [Abstract][Full Text] [Related]
17. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X
Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464
[TBL] [Abstract][Full Text] [Related]
18. Screening protective miRNAs and constructing novel lncRNAs/miRNAs/mRNAs networks and prognostic models for triple-negative breast cancer.
Zhao Y; Song Y; Zhang Y; Ji M; Hou P; Sui F
Mol Cell Probes; 2023 Dec; 72():101940. PubMed ID: 37871689
[TBL] [Abstract][Full Text] [Related]
19. Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes.
Liu Y; Cai Q; Bao PP; Su Y; Cai H; Wu J; Ye F; Guo X; Zheng W; Zheng Y; Shu XO
Breast Cancer Res Treat; 2015 Jul; 152(1):183-191. PubMed ID: 26062749
[TBL] [Abstract][Full Text] [Related]
20. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
